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of the ethnic categories. Only 15.6% and 9.7% of the patients
had lipid tests and LFTs within three months since the start 
of therapy. Non-Hispanic blacks were less likely to have lipid
tests compared to non-Hispanic whites (OR = 0.804; 95% CI,
0.653–0.990). Presence of coronary heart disease (OR = 1.305;
95% CI, 1.093–1.556) and lipid test prior to the start of therapy
(OR = 4.207; 95% CI, 3.607–4.908) were associated with an
increased likelihood of lipid tests after the start of therapy. Older
patients (OR = 0.987; 95% CI, 0.977–0.997) and non-Hispanic
blacks (OR = 0.543; 95% CI, 0.413–0.713) had a lower likeli-
hood of having LFTs than younger patients and whites. Presence
of hypertension (OR = 1.312; 95% CI, 1.081–1.592) and prior
LFTs (OR = 3.561; 95% CI, 2.939–4.315) were associated with
an increased likelihood of LFTs after the start of therapy. CON-
CLUSION: Monitoring of lipid levels and adverse events for
patients on statin therapy remains suboptimal. There exists an
ethnic disparity in the management of hyperlipidemia.
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OBJECTIVES: To examine effect of co-payment on the initia-
tion of statins after coronary heart disease (CHD) hospitali-
zation. METHODS: Medstat Marketscan commercial and
Medicare 1999–2002 databases including inpatient admission,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst CHD hospital admission was identiﬁed as the index hospi-
talization. The study sample consisted of adults who had no
statin use during the year prior to the index hospitalization and
had at least six-month follow up after discharge. The outcome
was the initiation of any statin prescription during six-month
follow up. Effect of co-payment on the initiation of statins was
examined by a multiple logistic regression, controlling for age,
gender, region, year of the index hospitalization, length of 
stay, baseline comorbidity, baseline number of drug therapeutic
classes, and baseline non-statin lipid-lowering drug use.
RESULTS: A total of 12,182 subjects met the inclusion criteria
and were included in the analysis. Only 5411 (44.41%) had ini-
tiated statin therapy within six-months after discharge. Com-
pared with those who had a co-payment less than or equal to
$10, subjects with a co-payment over $20 were about two thirds
less likely to initiate statin therapy (OR, 0.34; 95% CI,
0.29–0.39), while subjects with a co-payment between $10 to
$20 were about 14% less likely. (OR: 0.86; 95% CI, 0.76–0.97).
Other signiﬁcant factors were baseline comorbidities including
congestive heart failure, hypertension, diabetes, hyperlipidemia;
baseline number of drug therapeutic classes, baseline non-statin
lipid-lowering drug use, age, and year of hospitalization. CON-
CLUSIONS: Fewer than half the patients received statin therapy
after CHD hospitalization. Co-payment appears to be a signiﬁ-
cant barrier to the initiation of statins, even after adjusting for
other demographic and clinical variables.
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Many studies have shown that high serum concentrations of
LDL-C are a major risk factor for coronary heart disease (CHD)
and that lowering LDL-C levels will reduce the risk of major
coronary events. Despite the availability of the National Cho-
lesterol Education Program Adult Treatment Panel III (ATP III)
guidelines for the management of hyperlipidemia, most patients
do not achieve their target LDL goals. OBJECTIVE: To evalu-
ate the impact of clinical pharmacist intervention on LDL-C 
outcomes, in patients at high risk of cardiovascular events.
METHODS: Forty-six patients with clinical atherosclerosis, a
disease that confers high risk for CHD events, under the age of
70 with LDL >110mg/dL were identiﬁed from the data systems
of Maccabi Healthcare Services (study group). The clinical phar-
macist intervention consisted of meeting the physicians in order
to present and discuss information regarding the ATP III recom-
mendations on the management of hyperlipidaemia, and to go
over patients clinical charts. Meetings were followed by written
recommendations regarding LDL management and by periodic
telephone follow-up to ensure implementation of the recom-
mendations. Outcome analysis was based on a comparison
between the study group and a control group (169 patients with
similar characteristics). RESULTS: After 6-months follow-up
81% of the patients in the study group showed an improvement
in LDL levels, with 24% achieving the ATP III goal for high risk
patients of LDL <100mg/dL. In the control group the numbers
were 61% and 16% respectively. CONCLUSION: Results of
several studies evaluating intervention programs indicate that
pharmacists can play a key role in improving cholesterol man-
agement in lipid clinics, community pharmacies, or hospitals.
This study demonstrates for the ﬁrst time in Israel that clinical
pharmacist can have a positive impact on meeting LDL-C goals
and better treatment outcomes.
PCV36
CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC
TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR
EVENTS IN CLINICAL PRACTICE
Van Ganse E1, Souchet T2, Laforest L3, Moulin P4, Bertrand M5,
Le Jeunne P6, Chretin S3, De Pouvourville G7
1CHU Lyon, Pierre Bénite, France; 2Merck Sharp & Dohme—Chibret,
Paris, France; 3Pharmacoepidemiology, CHU-Lyon, Pierre Bénite,
France; 4Hopital Louis Pradel, Lyon, France; 5CHU-Lille, Lambersart,
France; 6Thales, Boulogne Billancourt, France; 7INSERM U 537,
Le Kremlin-Bicêtre, France
OBJECTIVES: This study investigated in French primary care,
the association between LDL-cholesterol goal attainment (LDL-
C < 130mg/dL in national guidelines) during three consecutive
years and occurrence of cardiovascular events (CV) in multiple
CV risk factor (three or more) patients, without coronary heart
disease history. METHODS: A total of 579 patients treated with
lipid lowering drugs (LLD) for three-years and with a yearly doc-
umented LDL-C (2000–2002) were consecutively included by
236 primary care physicians. Patients were classiﬁed into three
groups according to the number of consecutive years they
attained TO: all 3 years (TO+++: n = 145), only part of the time
(TO intermediate: n = 256), and never (TO---: n = 178). CV
risk factors and CV events (angina pectoris, myocardial infarc-
tion, heart failure, stroke, peripheral artery disease) occurring
during the last year of observation, 2002, were retrospectively
collected through computerized medical records (Thales data-
base) and a speciﬁc questionnaire. The risk of occurrence of a
CV events was studied according to TO status. Logistic regres-
sion model was used, to adjust for baseline differences in CV risk
factors. RESULTS: Only 25% of patients reached TO during all
three years. Patients with at least one CV event were 5.5%,
10.5% and 12.9% respectively in the TO+++, TO intermediate
and TO--- groups. Compared to TO+++, signiﬁcantly increased
risk of CV event was observed, both for TO intermediate (OR
